Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo

被引:217
作者
Ringshausen, Ingo
O'Shea, Cloclagh C.
Finch, Andrew J.
Swigart, Lamorna Brown
Evan, Gerard I.
机构
[1] Univ Calif San Francisco, Canc Res Inst, Ctr Comprehens Canc, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, Ctr Comprehens Canc, San Francisco, CA 94143 USA
关键词
D O I
10.1016/j.ccr.2006.10.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There is currently much interest in the idea of restoring p53 activity in tumor cells by inhibiting Hdm2/Mdm2. However, it has remained unclear whether this would also activate p53 in normal cells. Using a switchable enclogenous p53 mouse model, which allows rapid and reversible toggling of p53 status between wild-type and null states, we show that p53 is spontaneously active in all tested tissues of mdm2-deficient mice, triggering fatal pathologies that include ablation of classically radiosensitive tissues. In apoptosis-resistant tissues, spontaneous unbuffered p53 activity triggers profound inhibition of cell proliferation. Such acute spontaneous p53 activity occurs in the absence of any detectable p53 posttranslational modification, DNA damage, or p19(ARF) signaling and triggers rapid p53 degradation.
引用
收藏
页码:501 / 514
页数:14
相关论文
共 59 条
[1]  
Alarcón R, 1999, CANCER RES, V59, P6046
[2]   Chemosensitization by antisense oligonucleotides targeting MDM2 [J].
Bianco, R ;
Ciardiello, F ;
Tortora, G .
CURRENT CANCER DRUG TARGETS, 2005, 5 (01) :51-56
[3]   Post-translational modification of p53 in tumorigenesis [J].
Bode, AM ;
Dong, ZG .
NATURE REVIEWS CANCER, 2004, 4 (10) :793-805
[4]   Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death [J].
Boesten, L. S. M. ;
Zadelaar, S. M. ;
De Clercq, S. ;
Francoz, S. ;
van Nieuwkoop, A. ;
Biessen, E. A. L. ;
Hofmann, F. ;
Feil, S. ;
Feil, R. ;
Jochemsen, A. G. ;
Zurcher, C. ;
Havekes, L. M. ;
van Vlijmen, B. J. M. ;
Marine, J. -C .
CELL DEATH AND DIFFERENTIATION, 2006, 13 (12) :2089-2098
[5]   Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo [J].
Bottger, A ;
Bottger, V ;
Sparks, A ;
Liu, WL ;
Howard, SF ;
Lane, DP .
CURRENT BIOLOGY, 1997, 7 (11) :860-869
[6]   Tissue and cell-specific expression of the p53-target genes: bax, fas, mdm2 and waf1/p21, before and following ionising irradiation in mice [J].
Bouvard, V ;
Zaitchouk, T ;
Vacher, M ;
Duthu, A ;
Canivet, M ;
Choisy-Rossi, C ;
Nieruchalski, M ;
May, E .
ONCOGENE, 2000, 19 (05) :649-660
[7]   An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors [J].
Brummelkamp, TR ;
Fabius, AWM ;
Mullenders, J ;
Madiredjo, M ;
Velds, A ;
Kerkhoven, RM ;
Bernards, R ;
Beijersbergen, RL .
NATURE CHEMICAL BIOLOGY, 2006, 2 (04) :202-206
[8]   Small molecule antagonists of the MDM2 oncoprotein as anticancer agents [J].
Buolamwini, JK ;
Addo, J ;
Kamath, S ;
Patil, S ;
Mason, D ;
Ores, M .
CURRENT CANCER DRUG TARGETS, 2005, 5 (01) :57-68
[9]   ARF-BP1/mule is a critical mediator of the ARF tumor suppressor [J].
Chen, DL ;
Kon, N ;
Li, MY ;
Zhang, WZ ;
Qin, J ;
Gu, W .
CELL, 2005, 121 (07) :1071-1083
[10]   P53 α-helix mimetics antagonize p53/MDM2 interaction and activate p53 [J].
Chen, LH ;
Yin, H ;
Farooqi, B ;
Sebti, S ;
Hamilton, AD ;
Chen, JD .
MOLECULAR CANCER THERAPEUTICS, 2005, 4 (06) :1019-1025